Skip to content
Book an appointment

Semaglutide in children aged 6–11: weight benefits, questions about growth

A study in children with obesity shows a reduction in body mass index, but also frequent side effects and a need to monitor growth.

Dr Dimitrios Rigopoulos 22 November 2026 3 min read
Παιδί σχολικής ηλικίας και γονέας συζητούν με παιδίατρο σε ήρεμο ιατρείο.
In this article
  1. What the evidence shows
  2. How certain are the findings?
  3. Our view
  4. What this means for you

Semaglutide reduced body mass index in children aged 6–11 with obesity in a two-year study. The finding expands our understanding of potential treatments for younger children, but comes with frequent gastrointestinal symptoms and questions about growth. On its own, it is not a recommendation to prescribe the drug to this age group.

What the evidence shows

The STEP Young study included 167 children with obesity from 48 centers in nine countries, with an average age of 10 years. Of these, 112 received semaglutide and 55 received a placebo, a treatment containing no active ingredient. All children and their families received counseling on daily habits. Slightly more than half of the children had at least one obesity-related health problem.

Body mass index, or BMI, combines weight and height. In children, it is interpreted in relation to age and sex, rather than using the fixed thresholds applied to adults. At 68 weeks, average BMI decreased by 13.5% with semaglutide, while it increased by 2.7% with placebo. At 104 weeks, the corresponding changes were a decrease of 9.4% and an increase of 8.4%.

In simpler terms, at 68 weeks, around 38 out of every 100 children who received semaglutide were below the diagnostic threshold for obesity, compared with 2 out of every 100 in the other group. At two years, the figures were 33 and 2 out of every 100 children, respectively.

Side effects were common. Vomiting occurred in around 70 out of every 100 children receiving semaglutide, compared with 29 out of every 100 receiving placebo; diarrhea occurred in 62 versus 35, and nausea in 58 versus 24. Most symptoms were mild or moderate and temporary. Serious adverse events were recorded in 9% of each group.

How certain are the findings?

This was a randomized, double-blind study: treatment was assigned at random, and neither the participants nor the researchers knew which treatment was being given. This strengthens the reliability of the comparison. The results were published in the New England Journal of Medicine.

However, 167 children and two years of treatment are not enough to clarify all the long-term effects. Most participants were white children, while almost 40% of the placebo group stopped the injections by 104 weeks. There had also been no initial screening for eating disorders.

Height warrants particular attention: over two years, the median increase in height was 8.8 centimeters with semaglutide and 12.1 with placebo. Measures of bone maturation, bone density, and pubertal progression were similar. The interpretation that slower height gain reflects a normalization of growth remains a hypothesis, not a definitive answer.

Our view

We believe this is a meaningful finding, but not a reason to rush to generalize. The reduction in BMI was clear, but the success of a pediatric treatment cannot be judged on weight alone. Growth, nutrition, mental well-being, and tolerability are equally important.

In our view, neither downplaying the benefit nor presenting the drug as an easy solution helps families. These results do not prove that future illnesses are prevented or that the treatment is suitable for every child. The study does not amount to approval of semaglutide for use in children aged 6–11.

What this means for you

  • If you are concerned about your child’s weight, discuss their weight and height trends with their pediatrician, rather than focusing on a single measurement.
  • Do not start, stop, or change medication based on a news report. Children need an individualized medical assessment.
  • Continue to support healthy daily habits as a family, without blame or pressure on the child.
  • If your child is already receiving treatment, report repeated vomiting, diarrhea, or difficulty taking in fluids to their doctor and ask for guidance.
  • Discuss how height, growth, diet, and mental well-being will be monitored, particularly when a chronic condition is also present.

This article is for informational purposes and does not replace advice from your doctor.

Dr Dimitrios Rigopoulos
Written by Dr Dimitrios Rigopoulos Specialist in Internal Medicine, MD, PhD, Director of the 1st Department of Internal Medicine at NIMTS Hospital, SCOPE Certified by the World Obesity Federation. Biography

This article is for information only and does not replace an examination and advice from your doctor.